Development of a Screening Tool for the Risk of Vitamin D Deficiency
NCT ID: NCT04404842
Last Updated: 2020-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
190 participants
OBSERVATIONAL
2020-01-14
2022-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D Supplementation for the Prevention of Cardiovascular Risk
NCT02020694
Increased Risk of Severe Coronavirus Disease 2019 in Patients With Vitamin D Deficiency
NCT04403932
Intervention Study of Vitamin D Supplementation to Prevent Cardiovascular Disease
NCT03339427
The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors
NCT02750293
Predictive Questionnaire for Vitamin D Insufficiency in Healthy Adults
NCT02408679
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Therefore, all patients will receive the EVIDENCE Questionnaire which includes 19 items that investigate those factors that influence the production, absorption and intake of vitamin D:
* anthropometric data (weight, height, waist circumference, BMI),
* demographic information, such as latitude and phototype,
* dietary intake of vitamin D,
* health status and therapies,
* multivitamin or vitamin D supplementation,
* sun exposure habits according to the season, frequency and time of exposure, the body parts exposed, the sunscreens use and outdoor activities.
The aim of the study is to develop a questionnaire useful in screening the adequacy of vitamin D concentration in the adult population and to produce evidence of construct validity and concurrent validity of the questionnaire itself.
SAMPLE SIZE: Psychometric literature suggests enrolling around 5-10 subjects for each item. Considering the number of items in the questionnaire, equal to 19, the number of subjects to be enrolled will be approximately 190.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EvidenceQ Cohort
Adult subjects, aged over 18 years, male and female.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Absence of liver pathologies;
* Absence of kidney pathologies;
* Absence of intestinal malabsorption syndromes;
* Absence of bariatric surgery;
* Absence of cancer;
* Absence of primary hyperparathyroidism;
* Absence of extensive dermatological pathologies (e.g. psoriasis, atopic dermatitis, vitiligo)
* Absence of supplementation with multivitamin supplements or vitamin D;
* Absence of chronic drug therapy with: anticonvulsants, antipsychotics, glucocorticoids, immunosuppressive corticosteroids, anti-retrovirals, slimming, hypocolestrolemicants, laxatives (prolonged use);
* acceptance and sign of informed consent.
Exclusion Criteria
* Affected by liver pathologies;
* Affected by kidney pathologies;
* Affected by intestinal malabsorption syndromes;
* Affected by cancer;
* Affected by primary hyperparathyroidism;
* Affected by extensive dermatological pathologies (e.g. psoriasis, atopic dermatitis, vitiligo).
* Candidates and/or undergoing bariatric surgery;
* Supplementation with multivitamin or vitamin D;
* Chronic therapy with: anticonvulsants, antipsychotics, glucocorticoids, immunosuppressive corticosteroids, anti-retrovirals, slimming, hypocolestrolemizzanti, laxatives (prolonged use).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituti Clinici Scientifici Maugeri SpA
OTHER
University of Pavia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hellas Cena
Tenured researcher
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hellas Cena
Role: PRINCIPAL_INVESTIGATOR
Univeristy of Pavia, ICS Maugeri SpA SB
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituti Clinici Scientifici Maugeri SpA
Pavia, Lombardy, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
14052020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.